CD152 [CTLA-4] (human):Fc (human) (rec.)

CHF 110.00
In stock
CHI-HF-210A4-C100100 µgCHF 110.00
CHI-HF-210A4-C500500 µgCHF 320.00
More Information
Product Details
Synonyms CTLA-4
Product Type Protein
Properties
Source/Host CHO cells
Sequence

The extracellular domain of human CD152 [CTLA-4] (aa 37-160) is fused to the N-terminus of the Fc region of human IgG1.

Crossreactivity Human
Biological Activity

Binds both CD80 (B7-1) and CD86 (B7-2) with high affinity and inhibits CD28 signaling competitively. Kills the target cell completely.

Purity ≥98% (SDS-PAGE)
Endotoxin Content <0.06EU/μg protein (LAL test; Lonza).
Reconstitution Reconstitute at 1mg/ml in sterile water.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Protein Negative Control

Fc (human) IgG1 Control (rec.)

Other Product Data

NCBI reference NP_005205.2: CD152 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.

Product References
  1. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg: D.J. Lenschow, et al.; Science 257, 789 (1992)
  2. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement: V.L. Perez, et al.; Immunity 6, 411 (1997)
  3. Ligation of B7-1/B7-2 by Human CD4 T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells: D.H. Munn, et al.; J. Immunol. 172, 4100 (2004)
  4. CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters: B. Marinari, et al.; PNAS 101, 6098 (2004)
  5. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies: D. Schönfeld, et al.; PNAS 106, 8198 (2009)
  6. Structure prediction and expression of modified rCTLA4-Ig as a blocker for B7 molecules: H. Mahdizadeh, et al.; IJPR 2020
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.